BAJAJHCARE
BAJAJ HEALTHCARE LIMITED
Each stock's 10,000-path forecast, rendered as light.
BAJAJ HEALTHCARE LIMITED (BAJAJHCARE) Stock Analysis & Case Study
Is BAJAJHCARE a good buy? The data-driven verdict.
BAJAJ HEALTHCARE LIMITED (BAJAJHCARE) trades at ₹330,on the numbers it tread carefully, a Downstox Snapshot Score of 44/100.
On the numbers, BAJAJ HEALTHCARE LIMITED (BAJAJHCARE) tread carefully, a Downstox Snapshot Score of 44/100, weighing fairly valued at 19.7× earnings, ROE of 9.4%, a 49% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
BAJAJHCARE fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How BAJAJHCARE ranks against the 2,373 companies in our screener
- BAJAJHCARE's market cap of 1,110 Cr ranks in the 41st percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- BAJAJHCARE's book value of ₹158 ranks in the 66th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- BAJAJHCARE's promoter holding of 58.6% ranks in the 49th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- BAJAJHCARE's 3-year profit (PAT) growth of 3.0% ranks in the 32nd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- BAJAJHCARE's 3-year revenue growth of -2.0% ranks in the 20th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- BAJAJHCARE's debt-to-equity ratio of 0.47x is lower than 37% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is BAJAJHCARE overvalued? BAJAJHCARE P/E vs peers
BAJAJHCARE trades at 19.7× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
BAJAJHCARE share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 9.8y of BAJAJHCARE history (19%/yr drift, 53%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| BAJAJHCARE 2027 | ₹164 | ₹326 | ₹649 | -1% |
| BAJAJHCARE 2028 | ₹122 | ₹323 | ₹855 | -2% |
| BAJAJHCARE 2029 | ₹98 | ₹320 | ₹1,044 | -3% |
| BAJAJHCARE 2030 | ₹83 | ₹318 | ₹1,219 | -4% |
| BAJAJHCARE 2031 | ₹71 | ₹315 | ₹1,389 | -4% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability BAJAJHCARE goes up, or doubles?
The bull case for BAJAJHCARE
- BAJAJHCARE's P/E of 19.7x is lower than 63% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹1,044.
The bear case & risks
- BAJAJHCARE's return on equity of 9.4% ranks in the 45th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- High historical volatility (53%/yr) means a wide, bumpy range of outcomes, size positions accordingly.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹98.
BAJAJHCARE volatility & expected range, how bumpy is the ride?
Over the last 9.8 years BAJAJHCARE compounded at 19%/year with annualized volatility of 53%. That volatility implies a 1-year 80% range of ₹164-₹649, the honest backbone behind any single price target.
BAJAJHCARE price forecast, the full 60-month probability fan
BAJAJHCARE price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds BAJAJHCARE hits common targets within the simulated horizon?
Full multi-horizon detail on the BAJAJHCARE price target & forecast page.
BAJAJHCARE Piotroski F-Score: 5/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. BAJAJHCARE scores 5/8, mixed financial health.
BAJAJHCARE MTF margin & leverage across 9 brokers
Margin Trading Facility lets you buy BAJAJHCARE with part of the capital. Lower margin % = higher leverage. Rates compared across 9 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Zerodha | 38.07% | 2.6× |
| Groww | 38.32% | 2.6× |
| Dhan | 40.00% | 2.5× |
| Kotak Neo | 40.00% | 2.5× |
| Paytm Money | 41.17% | 2.4× |
| PocketfulCHEAPEST | 37.66% | 2.7× |
| Anand Rathi | 38.07% | 2.6× |
| Bajaj Broking | 47.00% | 2.1× |
| Share India | 38.27% | 2.6× |
Compare every broker on the BAJAJHCARE MTF page.
About BAJAJ HEALTHCARE LIMITED: sector, index & market-cap context
BAJAJ HEALTHCARE LIMITED (BAJAJHCARE) is a small-cap NSE-listed company, with a market capitalisation of ₹1,110 Cr. See more stocks on our screener.
How the BAJAJHCARE Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of BAJAJ HEALTHCARE LIMITED's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
BAJAJHCARE analysis, FAQs
Is BAJAJ HEALTHCARE LIMITED (BAJAJHCARE) a good buy?
On the numbers, BAJAJ HEALTHCARE LIMITED (BAJAJHCARE) tread carefully, a Downstox Snapshot Score of 44/100, weighing fairly valued at 19.7× earnings, ROE of 9.4%, a 49% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is BAJAJHCARE overvalued or undervalued?
BAJAJHCARE trades at 19.7× earnings, fairly valued versus the ~22× long-run Nifty average.
What is the BAJAJHCARE share price target for 2031?
BAJAJHCARE's probability-weighted 2031 median target is ₹315, with an 80% range of ₹71-₹1,389 (10,000-path Monte-Carlo).
What is the probability BAJAJHCARE doubles in 5 years?
The modelled probability of BAJAJHCARE reaching ₹659 (2×) within 5 years is 26%.
What is the bull case for BAJAJHCARE?
BAJAJHCARE's P/E of 19.7x is lower than 63% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
What are the risks in BAJAJHCARE?
BAJAJHCARE's return on equity of 9.4% ranks in the 45th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026. High historical volatility (53%/yr) means a wide, bumpy range of outcomes, size positions accordingly.